Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing Immunochina Closes Series D+ with at least $28 Million for CAR-T Drugs

publication date: Nov 2, 2022

Beijing Immunochina raised at least $28 million in a Series D+ round of to support the NDA filing and commercialization of its lead product, CAR-T IM19. The IM19 molecule, a CD19 CAR-T immunotherapy, was tested in patients with B-Cell Acute Lymphoblastic Leukemia and Non Hodgkin’s Lymphoma. Simcere partners the drug. The company's portfolio includes ten CAR-T assets. Immunochina’s latest financing was co-invested by Beijing Zhongguancun Science City Innovation Development and BCT Capital. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital